Fushine(SZ:300497) Zheng Quan Zhi Xing·2025-06-27 16:48Core Viewpoint - The document outlines the regulations and procedures for Jiangxi Fuxiang Pharmaceutical Co., Ltd. regarding the deferral and exemption of information disclosure, emphasizing the importance of protecting state secrets and commercial confidentiality [2][3][4]. Group 1: General Principles - The company aims to standardize the deferral and exemption of information disclosure to enhance regulatory oversight and protect investors' rights [2]. - The company will adhere to relevant laws and regulations, including the Shenzhen Stock Exchange's rules, when handling information disclosure deferrals and exemptions [2][3]. Group 2: Scope of Deferral and Exemption - Information that involves state secrets or could violate confidentiality regulations may be exempted from disclosure if sufficient evidence is provided [3][4]. - Commercial secrets can be deferred or exempted from disclosure if they meet specific criteria, such as potential harm to the company or others if disclosed [3][4]. Group 3: Internal Management Procedures - The company must carefully determine the scope of deferral and exemption, ensuring that it does not misuse these provisions [5]. - The board of directors will oversee the management of deferral and exemption matters, with the board secretary responsible for coordination [5][6]. Group 4: Documentation and Reporting - The company must maintain records of any deferred or exempted disclosures, including the type of information and the internal review process [6][7]. - If the reasons for deferral or exemption are no longer valid, the company must promptly disclose the information [6][7].